MedTrace Logo

Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19

NCT04912921 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2023-03-08

No results posted yet for this study

Summary

Two randomized controlled trials will be conducted to examine the effect of a food supplement on proinflammatory cytokines and biomarkers in an adult population recently diagnosed with COVID-19 who are asymptomatic or experiencing only mild symptoms. The supplement, palmitoylethanolamide (PEA), is marketed under the trademarked product with increased bioavailability and format versatility: Levagen+™ (Gencor Pacific Limited, Irvine, CA). The supplement curcumin is marketed under the trademarked product with increased bioavailability: HydroCurc (Gencor Pacific Limited, Irvine, CA)

Conditions

Interventions

DIETARY_SUPPLEMENT

palmitoylethanolamide

4 tablets taken daily (2 in the am and 2 in the pm)

DIETARY_SUPPLEMENT

Placebo

4 tablets taken daily (2 in am and 2 in pm)

DIETARY_SUPPLEMENT

Curcumin

500 mg HydroCurc® twice a day

DIETARY_SUPPLEMENT

Control (microcrystalline cellulose)

2 tablets taken daily

Sponsors & Collaborators

  • Arizona State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2022-05-15
Completion
2022-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912921 on ClinicalTrials.gov